Immix Biopharma subsidiary Nexcella awarded $8M CIRM grant for NXC-201 AL Amyloidosis trial

Immix Biopharma, Inc.

$8 million CLIN2 grant from California Institute for Regenerative Medicine to support NXC-201 CAR-T therapy for relapsed/refractory AL Amyloidosis.
NEXICART-2 U.S. Phase 1b/2 trial to evaluate NXC-201; builds on prior ex-U.S. data showing 92% overall response rate.
NXC-201 is the only CAR-T therapy in development for AL Amyloidosis and has Orphan Drug Designation from FDA and EMA.
No FDA approved drugs currently for relapsed/refractory AL Amyloidosis; CIRM grant adds non-dilutive funding to ongoing clinical program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.